HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 296/4/R1132    most recent 90874.2008v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Novak, M. L Articles by Koh, T. J. Search for Related Content PubMed PubMed Citation Articles by Novak, M. L Articles by Koh, T. J.

EXERCISE AND RESPIRATORY PHYSIOLOGY

COX-2 inhibitor reduces skeletal muscle hypertrophy in mice

¹Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Illinois; ²Department of Kinesiology, University of Toledo, Toledo, Ohio; ³Department Bioengineering, University of California, San Diego, California; and ⁴Department of Comparative Biosciences, University of Wisconsin, Madison, Wisconsin

Submitted 28 October 2008 ; accepted in final form 21 January 2009

Anti-inflammatory strategies are often used to reduce muscle pain and soreness that can result from high-intensity muscular activity. However, studies indicate that components of the acute inflammatory response may be required for muscle repair and growth. The hypothesis of this study was that cyclooxygenase (COX)-2 activity is required for compensatory hypertrophy of skeletal muscle. We used the synergist ablation model of skeletal muscle hypertrophy, along with the specific COX-2 inhibitor NS-398, to investigate the role of COX-2 in overload-induced muscle growth in mice. COX-2 was expressed in plantaris muscles during compensatory hypertrophy and was localized mainly in or near muscle cell nuclei. Treatment with NS-398 blunted the increases in mass and protein content in overloaded muscles compared with vehicle-treated controls. Additionally, the COX-2 inhibitor decreased activity of the urokinase type plasminogen activator, macrophage accumulation, and cell proliferation, all of which are required for hypertrophy after synergist ablation. Expression of insulin-like growth factor-1 and phosphorylation of Akt, mammalian target of rapamycin, and p70S6K were increased following synergist ablation, but were not affected by NS-398. Additionally, expression of atrogin-1 was reduced during hypertrophy, but was also not affected by NS-398. These results demonstrate that COX-2 activity is required for skeletal muscle hypertrophy, possibly through facilitation of extracellular protease activity, macrophage accumulation, and cell proliferation.

inflammation; nonsteroidal anti-inflammatory drug; macrophage; muscle growth

This article has been cited by other articles:

				U. R. Mikkelsen, H. Langberg, I. C. Helmark, D. Skovgaard, L. L. Andersen, M. Kjaer, and A. L. Mackey Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise J Appl Physiol, November 1, 2009; 107(5): 1600 - 1611. [Abstract] [Full Text] [PDF]

				E. Castillero, A. I. Martin, M. Lopez-Menduina, M. A. Villanua, and A. Lopez-Calderon Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1322 - R1331. [Abstract] [Full Text] [PDF]

				G. Paulsen, F. Lauritzen, M. L. Bayer, J. M. Kalhovde, I. Ugelstad, S. G. Owe, J. Hallen, L. H. Bergersen, and T. Raastad Subcellular movement and expression of HSP27, {alpha}B-crystallin, and HSP70 after two bouts of eccentric exercise in humans J Appl Physiol, August 1, 2009; 107(2): 570 - 582. [Abstract] [Full Text] [PDF]